Despite several limitations our pooled-analysis shows that tumor PD-L1 expression, IHC cut-off >1%, is associated with significantly higher ORRs to anti PD-1/PD-L1 MoAbs, in pre-treated NSCLC patients. This evidence concerns the gene PDCD1 and neoplasm.